Patients who have malignant tumor with WT1-positive. Patients who have ever received DC vaccination with WT1 peptide, or WT1 antigen.
Conditions
Interventions
PepTivator(R) WT1-added Autologous gamma/delta T cells are injected on day0, day28.
Sponsors
Seta Clinic Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with histologically confirmed malignant tumors. 2)Patients who recognized WT1 expression on tumor tissue. Blood cancer patients who recognized WT1 expression in tumor cells. 3)Patients with a past history of a positive DTH. 4)Performance Status is 0-2. 5)No serious abnormality in bone marrow, liver, and renal functions. 6)Informed consent has been obtained .
Exclusion criteria
Exclusion criteria: Patients who have: 1)Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them 2)Serious drug allergy 3)Active autoimmune disease 4)Active enteritis 5)Positive for HIV or HTLV-1 6)Received continuous systemic steroids 7)Other cancers 8)Active infections 9)Serious cardiac disease 10)Pregnant or lactating 11)Any reason why, in the opinion of the investigator, the patient should not participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological responses Efficacy | — |
Countries
Japan
Contacts
Public ContactHiroshi Ibe
Seta Clinic Group Center for Clinical Trials and Research
Outcome results
None listed